Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions - PubMed (original) (raw)
. 2008 May 1;180(9):6116-31.
doi: 10.4049/jimmunol.180.9.6116.
Yong F Li, Mona El-Gamil, Yangbing Zhao, Jennifer A Wargo, Zhili Zheng, Hui Xu, Richard A Morgan, Steven A Feldman, Laura A Johnson, Alan D Bennett, Steven M Dunn, Tara M Mahon, Bent K Jakobsen, Steven A Rosenberg
Affiliations
- PMID: 18424733
- PMCID: PMC2424230
- DOI: 10.4049/jimmunol.180.9.6116
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
Paul F Robbins et al. J Immunol. 2008.
Abstract
Single and dual amino acid substitution variants were generated in the TCR CDRs of three TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR gene-modified T cells to the cognate Ag complex were identified using a rapid RNA-based transfection system. The screening of a panel of variants of the 1G4 TCR, that recognizes a peptide corresponding to amino acid residues 157-165 of the human cancer testis Ag NY-ESO-1 (SLLMWITQC) in the context of the HLA-A*02 class I allele, resulted in the identification of single and dual CDR3alpha and CDR2beta amino acid substitutions that dramatically enhanced the specific recognition of NY-ESO-1(+)/HLA-A*02(+) tumor cell lines by TCR gene-modified CD4(+) T cells. Within this group of improved TCRs, a dual substitution in the 1G4 TCR CDR3alpha chain was identified that enhanced Ag-specific reactivity in gene-modified CD4(+) and CD8(+) T cells. Separate experiments on two distinct TCRs that recognize the MART-1 27-35 (AAGIGILTV) peptide/HLA-A*02 Ag complex characterized single amino acid substitutions in both TCRs that enhanced CD4(+) T cell Ag-specific reactivity. These results indicate that simple TCR substitution variants that enhance T cell function can be identified by rapid transfection and assay techniques, providing the means for generating potent Ag complex-specific TCR genes for use in the study of T cell interactions and in T cell adoptive immunotherapy.
Figures
FIGURE 1
Generation of AAS variants of 1G4, DMF5, and DMF4 TCRs (A). Pairs of oligonucleotide primers designated _α_1 and _α_2 or _β_1 and _β_2 were used to amplify regions of TCR _α_-or _β_-chain sequences, respectively, that were upstream of the AAS. The AAS were encoded within a primer that partially overlapped with the _α_2 or _β_2 primer, designated _α_3 or _β_3, that was used to carry out a second PCR with primer _α_4 or _β_4. The products of the first two PCR were combined and amplified using primers _α_1 and _α_4 or _β_1 and _β_4. The nucleotide and amino acid sequences of the 1G4, DMF5, and DMF4 α and β TCR chains are presented in B, C, and D, respectively, and specific primers used to generate the AAS variants detailed in Table I.
FIGURE 2
Rapid screening of NY-ESO-1/HLA-A*02-reactive TCR 1G4 CDR3_α_ variants in CD8+ and CD4+ T cells. T cells were activated with anti-CD3 Ab and isolated CD8+ (A and B) or CD4+ (C) T cells were cotransfected with RNA 1G4 TCR _α_-chain constructs encoding AAS within the CDR3 region along with a WT 1G4 TCR _β_-chain RNA construct. Transfected T cells were incubated overnight with T2 cells pulsed with the indicated concentrations of NY-ESO-1 peptide or with 1 _μ_M control peptide, gp100:154-162 (A), or with HLA-A*02+ melanoma and breast cancer target cell lines that did or did not also express the NY-ESO-1 transcript (B and C). The release of IFN-γ was measured the following day.
FIGURE 3
Peptide titration of responses of CD8+ and CD4+ T cells transfected with NY-ESO-1/HLA-A*02-reactive 1G4 WT, CDR2_β_, and CDR3_α_ TCR variants. T cells were activated with anti-CD3 Ab and isolated CD8+ (A and B) or CD4+ (C and D) T cells were cotransfected with RNA-encoding TCR constructs containing substitutions in the 1G4 _α_- or _β_-chains along with the complementary 1G4 WT TCR chain. The releases of IFN-γ in response to T2 cells pulsed with varying doses of the NY-ESO-1 peptide or with 10 nM control HLA-A*02-binding peptide from gp100 corresponding to amino acids 154-163 (KTWGQYWQV) were measured the following day.
FIGURE 4
Rapid screening of NY-ESO-1/HLA-A*02-reactive TCR 1G4 CDR2 and CDR3 β variants in CD8+ and CD4+ T cells. T cells were activated with anti-CD3 Ab and isolated CD8+ (A-C) or CD4+ (D) T cells were cotransfected with RNA 1G4 TCR _β_-chain constructs encoding AAS within the CDR2 or CDR3 regions along with a WT 1G4 TCR _α_-chain RNA construct. Transfected T cells were incubated overnight with T2 cells pulsed with the indicated concentrations of NY-ESO-1 peptide or a control peptide, gp100:154-162 (A and B), or HLA-A*02+ melanoma target cell lines that did or did not also express NY-ESO-1 transcript (C and D). The release of IFN-γ was measured the following day.
FIGURE 5
Effects of NY-ESO-1/HLA-A*02-reactive TCR 1G4 CDR3_α_ and CDR2_β_ variants on the cytolytic activity of CD8+ and CD4+ T cells. The cytolytic activities of anti-CD3 Ab stimulated CD8+ (A) and CD4+ (B) T cells cotransfected with 1G4 WT and variant TCRs to the HLA-A*02+ and NY-ESO-1+ melanoma cell lines 624.38 and A375 as well as the response to the HLA-A*02+, but the NY-ESO-1- renal cell carcinoma line 2661R was measured in standard 4-h 51Cr-release cell lysis assays.
FIGURE 6
Effects of NY-ESO-1/HLA-A*02-reactive 1G4 WT and variant TCRs on CD8+ and CD4+ T cell activity following retroviral transduction. Anti-CD3 Ab stimulated PBMC were transduced on days 2 and 3 with retroviral supernatants that coexpressed either the 1G4 WT α and β, α_95:LY and WT β, or WT_α and _β_51:AI TCR chains. Ten days following anti-CD3 Ab stimulation, CD8+ (A and C) and CD4+ (B and D) T cells were separated and were tested 4 days later for their ability to release IFN-γ (A and B) or IL-2 (C and D) in response to melanoma, lung carcinoma, and renal cell carcinoma cell lines. The results presented are representative of those obtained following the transduction of three samples of PBMC. Cell surface TCR expression was evaluated by FACS analysis of V_β_13 as well as NY-ESO-1/HLA-*02 tetramer staining 10 days following anti-CD3 Ab stimulation, and coculture assays were initiated on day 13.
FIGURE 7
Rapid screening of MART-1/HLA-A*02-reactive TCR DMF5 and DMF4 WT and CDR2_β_ variants. T cells were activated with anti-CD3 Ab and isolated CD8+ (A and C) and CD4+ (B and D) T cells were cotransfected with RNA constructs encoding the WT α, along with either the WT β_-chain or CDR2_β variant chains generated from either the DMF5 TCR (A and B) or the DMF4 TCR (C and D). Transfected T cells were evaluated the following day for their ability to generate IFN-γ in response to melanoma target cell lines.
FIGURE 8
Effects of MART-1/HLA-A*02-reactive TCR DMF4 and DMF5 CDR2_β_ variants on the cytolytic activity of CD8+ and CD4+ T cells. The cytolytic activities of CD8+ (A and B) and CD4+ (C and D) T cells transfected with RNA encoding the DMF4 and DMF5 WT and variant TCRs to the HLA-A*02+ and MART-1+ melanoma cell line 624.38 (A and C) and to the HLA-A*02+ but MART-1- tumor cell line renal cell carcinoma 2661R (B and D) were evaluated in standard 4-h 51Cr-release cell lysis assays.
FIGURE 9
Peptide titration of responses of CD8+ and CD4+ T cells transfected with MART-1/HLA-A*02-reactive DMF4 and DMF5 WT TCRs and their CDR2_β_ variants. T cells were activated with anti-CD3 Ab and isolated CD8+ (A) or CD4+ (B) cells were cotransfected with RNA encoding TCR constructs containing substitution of DMF4 or DMF5 _β_-chains along with the complementary DMF4 or DMF5 WT _α_-chains. The releases of IFN-γ in response to T2 cells pulsed with varying doses of the MART-1 peptide or with a 1 _μ_M control HLA-A*02-binding peptide corresponding to tyrosinase residues 369-377 (YMDTMSQV) were measured the following day.
Similar articles
- Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide.
Shenderov E, Kandasamy M, Gileadi U, Chen J, Shepherd D, Gibbs J, Prota G, Silk JD, Yewdell JW, Cerundolo V. Shenderov E, et al. J Immunother Cancer. 2021 Jun;9(6):e002544. doi: 10.1136/jitc-2021-002544. J Immunother Cancer. 2021. PMID: 34088742 Free PMC article. - A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.
Matsuzaki J, Tsuji T, Chodon T, Ryan C, Koya RC, Odunsi K. Matsuzaki J, et al. J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y. J Immunother Cancer. 2019. PMID: 30626427 Free PMC article. - Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA. Parkhurst MR, et al. Clin Cancer Res. 2009 Jan 1;15(1):169-80. doi: 10.1158/1078-0432.CCR-08-1638. Clin Cancer Res. 2009. PMID: 19118044 Free PMC article. - Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
D'Ippolito E, Wagner KI, Busch DH. D'Ippolito E, et al. Int J Mol Sci. 2020 Nov 6;21(21):8324. doi: 10.3390/ijms21218324. Int J Mol Sci. 2020. PMID: 33171940 Free PMC article. Review. - T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.
Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A. Klebanoff CA, et al. Nat Rev Drug Discov. 2023 Dec;22(12):996-1017. doi: 10.1038/s41573-023-00809-z. Epub 2023 Oct 27. Nat Rev Drug Discov. 2023. PMID: 37891435 Free PMC article. Review.
Cited by
- Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy.
Yao Z, Zeng Y, Liu C, Jin H, Wang H, Zhang Y, Ding C, Chen G, Wu D. Yao Z, et al. J Exp Clin Cancer Res. 2024 Sep 28;43(1):266. doi: 10.1186/s13046-024-03195-5. J Exp Clin Cancer Res. 2024. PMID: 39342365 Free PMC article. Review. - Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies.
Kapetanovic E, Weber CR, Bruand M, Pöschl D, Kucharczyk J, Hirth E, Dietsche C, Khan R, Wagner B, Belli O, Vazquez-Lombardi R, Castellanos-Rueda R, Di Roberto RB, Kalinka K, Raess L, Ly K, Rai S, Dittrich PS, Platt RJ, Oricchio E, Reddy ST. Kapetanovic E, et al. Nat Biomed Eng. 2024 Sep 25. doi: 10.1038/s41551-024-01255-x. Online ahead of print. Nat Biomed Eng. 2024. PMID: 39322719 - Development of a highly sensitive platform for protein-protein interaction detection and regulation of T cell function.
Hayashi H, Mak TW, Tanaka Y, Kubo Y, Izumida M, Urae R, Matsuyama T. Hayashi H, et al. Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2318190121. doi: 10.1073/pnas.2318190121. Epub 2024 Aug 6. Proc Natl Acad Sci U S A. 2024. PMID: 39106307 Free PMC article. - Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma.
Lai TJ, Sun L, Li K, Prins TJ, Treger J, Li T, Sun MZ, Nathanson DA, Liau LM, Lai A, Prins RM, Everson RG. Lai TJ, et al. Cancer Res Commun. 2024 Jul 1;4(7):1834-1849. doi: 10.1158/2767-9764.CRC-23-0566. Cancer Res Commun. 2024. PMID: 38856710 Free PMC article. - NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.
Oh J, Kirsh C, Hsin JP, Radecki KC, Zampieri A, Manry D, Ando Y, Miller S, Chan J, McLeod E, Cunningham KM, Wong LM, Xu H, Kamb A. Oh J, et al. iScience. 2024 May 7;27(6):109913. doi: 10.1016/j.isci.2024.109913. eCollection 2024 Jun 21. iScience. 2024. PMID: 38799557 Free PMC article.
References
- Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y. Ligand recognition by αβ T cell receptors. Annu. Rev. Immunol. 1998;16:523–544. - PubMed
- Manning TC, Kranz DM. Binding energetics of T-cell receptors: correlation with immunological consequences. Immunol. Today. 1999;20:417–422. - PubMed
- van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 2003;21:659–684. - PubMed
- Rudolph MG, Luz JG, Wilson IA. Structural and thermodynamic correlates of T cell signaling. Annu. Rev. Biophys. Biomol. Struct. 2002;31:121–149. - PubMed
- Savage PA, Davis MM. A kinetic window constricts the T cell receptor repertoire in the thymus. Immunity. 2001;14:243–252. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials